The six-transmembrane epithelial antigen of prostate family member 3 (STEAP3) was first discovered in prostate tissues as a potential target for prostate cancer immunotherapy [15], also known as tumor suppressor activated pathway-6 (TSAP6). This evidence concerns the gene STEAP3 and Familial prostate cancer.